Allergan Unanimously Rejects Valeant’s Bid

REPLAY VIDEO
Your next video will start in
Pause

Recommended Videos

  • Info

  • Comments

May 12 (Bloomberg) -- Allergan board says the Valeant bid “substantially undervalues” the company and creates significant risks and uncertainties and is not in best interests of the company and shareholders. Tom Keene reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

Advertisement

BTV Channel Finder

Channel_finder_loader

ZIP is required for U.S. locations

Bloomberg Television in   change